Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. Januar 2021 10:10 ET | Quelle: NX Development Corp.

NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma

Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) -- NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for...
17. November 2020 14:12 ET | Quelle: NX Development Corp.

NX Development Corp. (NXDC) Launches Gleolan (aminolevulinic acid HCl) Meningioma Phase III Clinical Trial (NXDC-MEN-301)

Lexington, KY, Nov. 17, 2020 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first...
03. Oktober 2019 12:58 ET | Quelle: NX Development Corp.

Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization

Lexington, KY, Oct. 03, 2019 (GLOBE NEWSWIRE) -- NX Development Corp (NXDC), a life sciences company based in Lexington, KY, today announced Baptist Health Lexington is the first hospital in state...